Overall, these studies suggest that Arl8b together with other biomarkers might have potential as a novel CSF biomarker for patient stratification, facilitating the measurement of abnormal lysosome structures, which form early in neurons and progressively accumulate in AD patient brains. The gene discussed is ARL8B; the disease is Alzheimer disease.